Calretinin: A novel immunocytochemical marker for mesothelioma

American Journal of Surgical Pathology

Volumn 20, Issue 9, 1996, Pages 1037-1046

  Doglioni, Claudio ^a   Dei Tos, Angelo P ^a   Laurino, Licia ^a   Luzzolino, Paolo ^a   Chiarelli, Concetta ^a   Celio, Marco R ^a   Viale, Giuseppe ^a   RcPath, M ^a,b,c,d  

^a City Hospital of Belluno   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c UNIVERSITY OF FRIBOURG   (Switzerland)

^d EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

Calretinin; Immunocytochemical markers for mesothelioma; Immunohistochemistry; Malignant mesothelioma; Metastatic adenocarcinoma

Indexed keywords

CALRETININ; MONOCLONAL ANTIBODY;

ADENOCARCINOMA; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; HUMAN; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; MESOTHELIOMA; PLEURA EFFUSION;

ADENOCARCINOMA; CALCIUM-BINDING PROTEIN, VITAMIN D-DEPENDENT; DIAGNOSIS, DIFFERENTIAL; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MESOTHELIOMA; PREDICTIVE VALUE OF TESTS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 0029819215     PISSN: 01475185     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000478-199609000-00001     Document Type: Article

References (48)

1. Amin KM, Litzky LA, Smythe WR, et al. Wilms' tumor susceptibility (WT1) gene products are selectively expressed in malignant mesothelioma. Am J Palhol 1995;146:344-56.
2. Andressen C, Blumcke I, Celio MR. Calcium-binding proteins: selective markers of nerve cells. Cell Tissue Res 1993; 271:181-208.
3. Bedrossian CW, Bonsib S, Moran C. Differential diagnosis between mesothelioma and adenocarcinoma: a multimodal approach based on ultrastructure and immunocytochemistry. Semin Diagn Palhol 1992;9:124-10.
4. Brown RW, Clark GM, Tandon AK, Allred DC. Multiplemarker immunohistochemical phenotypes distinguishing malignant pleural mesothelioma from pulmonary adenocarcinoma. Hum Patlwl 1993;24:347-54.
5. Bruening W, Gros P, Sato T, et al. Analysis of the Ilpl3 Wilms' tumor suppressor gene (WT1) in ovarian tumors. Cancer Invest 1993;11:393-9.
6. Chang K, Pai LH, Pass H, et al. Monoclonal antibody Kl reacts with epithelial mesothelioma but not with lung adenocarcinoma. Am J Surg Palhol 1992;16:259-68.
7. Clark SP, Chou ST, Martin TJ, Danks JA. Parathyroid hormone-related protein antigen localization distinguishes between mesothelioma and adenocarcinoma of the lung. J Pathol 1995;176:161-5.
8. Collins CL, Ordonez NG, Schaefer R, et al. Thrombomodulin expression in malignant pleural mesothelioma and pulmonary adenocarcinoma. Am J Patlwl 1992;141:827-33.
9. Dechesne CJ, Winsky L, Kim HN, et al. Identification and ultrastructural localization of calretinin-like calcium-binding protein (Protein 10) in the guinea pig and rat inner ear. Brain Res 1991;560:139-48.
10. Dejmek A, Hjerpe A. Immunohistochemical reactivity in mesothelioma and adenocarcinoma: a stepvvise logistic regression analysis. APMIS 1994; 102:255-64.
11. Delahaye M, Hoogsteden HC, Van der Kwast TH. Immunocytochemistry of malignant mesothelioma: OV632 as a marker of malignant mesothelioma. J Patliol 1991;165:13743.
12. Doglioni C, Dell'Orto P, Coggi G, luzzolino P, Bontempini L, Viale G. Choroid plexus tumors. An immunocytochemical study with particular reference to the coexpression of intermediate filaments. Am J Pailwl l987;127:519-29.
13. Donna A, Bella PG, Bellingeri D, Marchesini A. New marker for mesothelioma: an immunoperoxidase study. J Clin Pailwl 1986:39:961-8.
14. Donna A, Betta P, Jones J. Verification of the histologie diagnosis of malignant in relation to the binding of an antimesothelial cell antibody. Cancer 1989;63:133l-6.
15. Donna A, Betta PG, Bellingeri D, Tallarida F, Pavesi M, Pastormerlo M. Cytologie diagnosis of malignant mesothelioma in serous effusions using an antimesothelial-cell antibody. Diagn Cytopatlwl 1992;8:36l-5.
16. Frisman DM, McCarthy WF, Schleiff P, Buckner SB, Nocito JD Jr, O'Leary TJ. Immunocytochemistry in the differential diagnosis of effusions: use of logic regression to select a panel of antibodies to distinguish adenocarcinomas from mesothelial proliferations. Mod Patlwl 1993;6:179-84.
17. Gaffey MJ, Mills SE, Swanson PE, Zarbo RJ, Shah AR, Wick MR. Immunoreactivity for BER-EP4 in adenocarcinomas, adenomatoid tumors, and malignant mesotheliomas. Am J Surf; Pailwl 1992;l6:593-9.
18. Gerald WL, Miller HK, Battifora H, Miettinen M, Suva EG, Rosai J. Intra-abdominal desmoplastic small round-cell tumor. Report of 19 cases of a distinctive type of high-grade polyphenotypic malignancy affecting young individuals. Am J Surn Patlwl 1991;15:499-513.
19. Gotzos V, Schwaller B, Hetzel N, Bustos-Castillo M, Celio MR. Expression of the calcium binding protein calretinin in WiDr cells and its correlation to their cell cycle. Exp Cell Res 1992:202:292-302.
20. Hsu SM, Raine L, Fanger H. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques. A comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem 1981:29:577-80.
21. Jackson DE, Mitchell CA, Bird P, Salem HH, Hayman JA. Immunohistochemical localization of thrombomodulin in normal human skin and skin tumours. J Patlwl 1995;175: 421-32.
22. Katzenstein AA, Weise DL, Fulling K, Battifora H. Socalled sclerosing hemangioma of the lung. Evidence for mesothelial origin. Am J Surf; Patlwl 1983:7:3-14.
23. Kortsik CS, Werner P, Freudenberg N, Virchow JC Jr, Kroegel C, Pott M, Matthys H. Immunocytochemical characterization of malignant mesothelioma and carcinoma metastatic to the pleura: 1OB3-a new tumor marker. Lung !995;173:79-87.
24. Leong AS, Vernon Roberts E. The immunohistochemistry of malignant mesothelioma. Palhol Anna 1994:29:157-79.
25. Menssen HD, Renkl HJ, Rodeck U, et al. Presence of Wilms' tumor gene (n7l) transcripts and the WT1 nuclear protein in the majority of human acute leukemias. Leukemia I995;9:1060-7.
26. Miettinen M, Kovatich AJ. HBME-I a monoclonal antibody useful in the differential diagnosis of mesothelioma, adenocarcinoma, and soft-tissue and bone tumors. Appl liniiuiiwhistocltem 1995;3:115-22.
27. Moch H, Oberholzer M, Dalquen P, Wegmann W, Gudat F. Diagnostic tools for differentiating between pleural mesothelioma and lung adenocarcinoma in paraffin embedded tissue. Part I: Immunohistochemical findings. Virclwws Arch A Patlwl Anat Histopatlwl 1993;423:19-27.
28. MotoyamaT, WatanabeT, Okazaki E.Tanaka N, Watanabe H. Immunohistochemical properties of malignant mesothelioma cells in histologie and cytologie specimens. Ada Cytol I995;39:164-70.
29. O'Hara CJ, Corson JM, Pinkus OS, Stahel RA. A monoclonal antibody that distinguishes epithelial-type malignant mesothelioma from pulmonary adenocarcinoma and extrapulmonary malignancies. Am J Patlwl 1990:136:421-8.
30. Ordonez NG, Zirkln R, Bloom R. Malignant small-cell epithelial tumor of the peritoneum coexpressing mesenchymal type intermediate filaments. J Surf; Pallwl 1989;I3:413-2I.
31. Parkash V, Gerald WL, Parma A, Miettinen M, Rosai J. Desmoplastic small round cell tumor of the pleura. Am J S urn Ptillwl 1995:19:659-65.
32. Parmentier M. Structure of the human cDNAs and genes coding for calbindin D28K and calretinin. Adv Exp Med Biol 1990:269:27-34.
33. Parmentier M, Lefort A. Structure of the human brain calcium-binding protein calretinin and its expression in bacteria. EurJ Biochem 1991:196:79-85.
34. Rodeck U, Bossier A, Kari C, et al. Expression of the wtl Wilms' tumor gene by normal and malignant human melanocytes. lut J Cancer I994;59:78-S2.
35. Rogers J, Khan M, Ellis J. Calretinin and other CaBPs in the nervous system. Adv Exp Med Biol 1990:269:195-203.
36. Ruitenbeek T, Gouw AS, Poppema S. Immunocytology of body cavity fluids. MOC-31, a monoclonal antibody discriminating between mesothelial and epithelial cells. Arch Pathol Lab Med 1994:118:265-9.
37. Schwaller B, Buchwald P, Blumcke I, Celio MR, Hunziker \V. Characterization of a polyclonal antiserum against purified human recombinant calcium binding protein calretinin. Cell Calcium 1993:14:639-18.
38. Sheibani K, Shin SS, Kezirian J, Weiss LM. Ber-EP4 antibody as a discriminant in the differential diagnosis of malignant mesothelioma versus adenocarcinoma. Am J Surf; Ptitliol 1991:15:779-84.
39. Sheibani K, Esteban JM, Bailey A, Battifora H, Weiss LM. Immunopathologic and molecular studies as an aid to the diagnosis of malignant mesothelioma. Hum Pallwl I992;23: 107-16.
40. Skov BG, Lauritzen AF, Hirsch F, Nielsen HW. The histopathological diagnosis of malignant mesothelioma v. pulmonary adenocarcinoma: reproducibility of the histopathological diagnosis, Histopailwlogy 1994:24:553-7.
41. Skov BG, Lauritzen AF, Hirsch FR, Skov T, Nielsen HW. Differentiation of adenocarcinoma of the lung and malignant mesothelioma: predictive value and reproducibility of immunoreactive antibodies. Hislapathology 1994:25:431-7.
42. Skov BG. Stahel RA, Hirsch F. MEI-antibody labelling of primary bronchogenic tumours and extrapulmonary malignancies. Lung Cancer 1994:11:221-7.
43. Soosay ON, Griffiths M, Papadaki L, Happerfield L, Bobrow L. The differential diagnosis of epithelial-type mesothelioma from adenocarcinoma and reactive mesothelial proliferation. J Patlwl 1991:163:299-305.
44. Stoop JA, Hendriks JG, Berends D. Identification of malignant cells in serous effusions using a panel of monoclonal antibodies Ber-EP4, MCA-b-12 and EMA. Cytopatholngy 1992:3:297-302.
45. Strauss Kl, Isaacs KR, Ha QN, Jacobowitz DM. Calretinin is expressed in the Leydig cells of rat testis. Bioch Biophys Ada 1994:1219:435-40.
46. Tuttle SE, Lucas JG, Bucci DM, Schlom J, Primus J. Distinguishing malignant mesothelioma from pulmonary adenocarcinoma: an immuno-histochemical approach using a panel of monoclonal antibodies. Surf; Oncol 1990:45:72-8.
47. Wirth PR, Legier J, Wright GL Jr. Immunohistochemical evaluation of seven monoclonal antibodies for differentiation of pleural mesothelioma from lung adenocarcinoma. Cancer 1991:67:655-62.
48. Yamada T, Jiping J, Endo R, Gotoh M, Shimosato Y, Hirohashi S. Molecular cloning of a cell-surface glycoprotein that can potentially discriminate mesothelium from epithelium: its identification as vascular cell adhesion molecule I. Br J Cancer I995;71:562-70.